- PL BioScience introduces the world’s first artificial Human Platelet Lysate (HPL), a crucial component for cell-based pharmaceutical research and production, developed using artificial platelet technology from its Korean partner, DewCell Biotherapeutics.
- While donor-derived, natural HPL already offers improved safety and sustainability compared to animal-derived cell culture supplements, artificial HPL provides a fully lab-created, scalable source.
- The artificial HPL, produced using PL BioScience’s unique method and additives, enhances cell performance beyond that of natural HPL while further improving safety and consistency.
- The technology will be presented today at 6:15 pm CDT at the International Society for Cell & Gene Therapy (ISCT) conference in New Orleans.
AACHEN, Germany, May 08, 2025 — PL BioScience GmbH, a German life science company specializing in Human Platelet Lysate (HPL) production and development for cell expansion, today announced the groundbreaking creation of an artificial HPL cell culture solution. Collaborating with DewCell Biotherapeutics (DewCell), a Korean biotech firm pioneering artificial platelet generation from stem cells in a reactor, PL BioScience has developed a proprietary method to transform these lab-grown platelets into a potent cell culture supplement. Manufactured in Germany using raw materials from DewCell, this innovative technology presents a scalable, safe, and animal-free alternative to Fetal Calf/Bovine Serum (FCS/FBS) and natural, donor-derived HPL for applications in regenerative medicine, cell therapy, and biopharmaceuticals. A patent application for the process has been submitted.
“Cell culture innovation is vital for advancing modern medicine, drug discovery, and our understanding of complex biological systems,” stated Dr. Hatim Hemeda, Chief Executive Officer of PL BioScience. “We are proud to contribute to the field with the first scalable artificial HPL solution, which can be produced in almost unlimited quantities in the mid-term to satisfy the expanding needs of the biopharmaceutical industry.”
He further added, “We are confident that the synergy between DewCell’s pioneering technology and our cell culture expertise will initiate a new era in regenerative medicine and cell therapy manufacturing.”
Dr. Hemeda will present this novel technology at the International Society for Cell & Gene Therapy (ISCT) conference in New Orleans in an oral presentation titled:
Innovating A Xeno-Free Revolution for Cell Therapies – Human Platelet Lysate
May 8, 2025, 6:15 PM CT, Global Showcase Theater B
HPL is a safe and effective cell culture supplement that serves as an alternative to FBS/FCS. Natural HPL is derived from donated human blood platelets that are expired and unsuitable for transfusion, making it a sustainable but limited resource. Through its proprietary synthetic HPL production technology, combined with DewCell’s artificial platelet technology, PL BioScience overcomes this limitation, delivering a fully scalable, high-performance cell culture supplement for biopharmaceutical applications.
About Human Platelet Lysate:
Human Platelet Lysate (HPL) is a cutting-edge, human-derived cell culture supplement utilized to support cell growth and expansion in research and clinical development, particularly in cell therapy, stem cell research, and regenerative medicine. Natural HPL is produced from donated human blood platelets that are no longer usable for transfusions and would otherwise be disposed of, rendering it a sustainable but finite alternative to animal-derived cell culture supplements. PL BioScience has developed a next-generation, fully artificial alternative made from lab-grown platelets to ensure a reliable future supply.
In cell culture, HPL provides crucial growth factors and nutrients that encourage robust and healthy cell proliferation. Compared to conventional products like Fetal Bovine Serum (FBS), which is extracted from unborn calves, HPL provides more consistent cell growth results, is free of animal-derived pathogens, and aligns with the increasing demand for ethically responsible and animal-free laboratory practices.
ELAREM™, PL BioScience’s line of xeno-free HPL products, can be used from initial research phases to the production of cell-based therapies under Good Manufacturing Practice (GMP) conditions for patient treatment.
About PL BioScience:
PL BioScience GmbH, a life science company based in Aachen, Germany, specializes in the production and development of Human Platelet Lysate (HPL). The company has pioneered a proprietary technology for producing fully artificial HPL, enabling a completely lab-made, scalable supply of HPL in the future.
PL BioScience currently offers a comprehensive portfolio of donor-derived, natural HPL products designed for various applications. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ELAREM™ ensures seamless translation of regenerative medicine advancements from the laboratory to patients in need. PL BioScience produces the only globally patented gamma-irradiated HPL product, ELAREM™ Ultimate-FD PLUS.
For more information on PL BioScience and the ELAREM™ product offerings, visit:
Contact:
Dr. Hatim Hemeda, CEO
PL BioScience GmbH
+49(0)24195719-100
Media contact:
MC Services AG
Raimund Gabriel, Dr. Regina Lutz
+49 (0)89 210 228 0
US: Catherine Featherston
+1-203-444-4393
E-Mail:
